Overactive Bladder
Conditions
Keywords
Overactive bladder, Botox, TC-3 Gel, Intravesical, UroGen Pharma, Botulinum Toxin, Urgency, OAB, Incontinence, I-QOL, KHQ, TBS, RTG
Brief summary
The study will investigate the safety and efficacy of UroGen's TC-3 Gel for sustained release of Botulinum Toxin A (BTX) in urinary bladder in patients with idiopathic overactive bladder.
Detailed description
Overactive bladder (OAB) is a syndrome, defined by the International Continence Society (ICS), as the presence of urinary urgency, usually accompanied by frequency and nocturia, with or without urgency urinary incontinence, in the absence of a urinary tract infection (UTI) or other obvious pathology. This study will evaluate a new of mode of treatment, with intravesical bladder instillation with Botox® mixed with TC-3 that may bypass the drawbacks of the current bladder injection treatment mode in OAB patients. Additionally it will provide preliminary safety and efficacy data that may serve as a basis for a larger study exploring safety and efficacy aspects of this new mode of treatment. 50 patients will be randomized in a horse race fashion in a \ 2:2:1 ratio. The patients will be screened for up to 3 weeks prior to treatment. The patients will be requested to stop their OAB medications 7 days prior to treatment visit. 20 patients will receive one instillation of 300U of BotuGel (60ml), 20 patients will receive one instillation of 400U of BotuGel (60ml) and 10 patients will receive one instillation of 60 ml RTGel-TC-3 Gel (Placebo), all patients will be followed up for safety and efficacy endpoints until 6 weeks post instillation.
Interventions
DRUG300 IU of BotuGelTM (60ml)
One intravesical instillation of 300 IU of botox in 60 ml of TC-3 gel
DRUG400 IU of BotuGelTM (60ml)
One intravesical instillation of 400 IU of botox in 60 ml of TC-3 gel
DEVICETC-3 Gel
Intravesical instillation of 60 ml TC-3 gel
Sponsors
UroGen Pharma Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
Main Inclusion Criteria: * Female patient 18 to 75 years old diagnosed with idiopathic OAB. * Patient has symptoms of OAB for ≥ 3 months prior to screening. * Patient is a non-responder to pharmacologic therapy or has intolerable side effects or is not compliant to the treatment. * On screening three-day voiding diary- Patient has a frequency of at least 8 micturitions per 24 hours & Total of ≥3 urgency urinary incontinence (UUI) episodes. * Patient is willing and able to initiate self catheterization post-treatment, if required. * Patients has PVR ≤100 ml. Patient with a single PVR of \>100 ml and followed by two consecutive PVR measurements of \<100 ml may be included in the study). Main
Exclusion criteria
* Patient currently uses CIC or indwelling catheter to manage their urinary incontinence * Patient who has clinically significant Bladder Outlet Obstruction (BOO). * Patient with active urinary tract infection. * OAB due to any known neurological reason. * Patient with 24-hour total urine volume voided greater than 3,000 ml as measured at screening visit. * Predominance of stress incontinence in the opinion of the investigator, determined by patient history. * Use of anticholinergics or other medications or therapies to treat symptoms of OAB within 7 days of screening. * Patient with prior botulinum toxin therapy of any serotype within 12 weeks for any indication. * Patient with prior use of Botulinum toxin therapy of any serotype for any urological condition. * Patient with previous pelvic radiation therapy. * Patient had been treated for two or more UTIs within last 6 months or use of prophylactic antibiotics to prevent chronic UTIs. * ANY condition identified which may cause overactive bladder symptoms
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Urinary retention | 6 weeks | Urinary retention events defined as a PVR \>200 and \<350 ml with patient reported symptoms that in the investigator's opinion require initiation of CIC, or PVR≥350 regardless of symptoms. |
| Urinary tract infection (UTI) events | 6 weeks | Urinary tract infection (UTI) events\* \*Asymptomatic bacteruria will not be considered UTI and will be reported as separate AEs. |
| Post-void residual (PVR) | 6 weeks | PVR-Change from baseline in PVR as measured by bladder ultrasonography at week 4 post instillation |
| Adverse events | 6 weeks | Adverse events during and post instillation procedure. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 3-day voiding Diary | Week 4 and 6 post-instillation | 3-day voiding Diary * Change from baseline in number of Urgency episodes and Urinary Incontinence episodes/24h * Change from baseline in number of voids/24h * Change from baseline in number of nocturnal voids per night (Based on individual patient's night and day hours) * Change from baseline in Mean volume voided per micturition/24h |
| Comparison of resulted delta scores between the treatment arms and Placebo | Week 4 and 6 post-instillation | — |
| Kings Health Questionnaire (KHQ score) comparing to baseline | Week 4 and 6 post-instillation | KHQ score comparing to baseline |
| Incontinence Quality of Life Questionnaire (I-QOL) | Week 4 and 6 post-instillation | I-QOL score comparing to baseline |
| Treatment Benefit Scale (TBS) | Week 4 and 6 post-instillation | Proportion of patients who had positive treatment response per Treatment Benefit Scale (TBS) |
Countries
Israel
Outcome results
None listed